{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-036005","form_type":"8-K/A","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2025-11-21T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.247313+00:00","generated_at":"2026-05-16T17:39:37.779465+00:00","sec_items":["9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NRx Pharmaceuticals amends 8-K to provide acquired Dura Medical's FY2024 financials","bullets":["Acquisition of Dura Medical closed September 8, 2025; this amendment provides required financials.","Dura Medical FY2024: net patient revenue $3.26M, net income $505K, total assets $1.37M.","Dura Medical for six months ended June 30, 2025 (unaudited) also provided.","Pro forma combined financials filed; reflects impact of acquisition on NRx statements.","Audited by Weinberg & Company; no material adjustments noted."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-036005","json":"https://secwatch.observer/filing/0001437749-25-036005.json","markdown":"https://secwatch.observer/filing/0001437749-25-036005.md","text":"https://secwatch.observer/filing/0001437749-25-036005.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/0001437749-25-036005-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000143774925036005/nrxp20251118_8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T17:39:37.779465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}